Introduction: This literature survey aims to extend the comprehensive survey performed by
Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from …

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a
promising candidate for the treatment of both somatic and psychiatric disorders. The aim of …

(1) Background: With the massive demand for the use and commercialization of medicinal
cannabidiol (CBD) products, new randomized clinical trials (RCTs) are being published …

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application
in a wide‐variety of contexts; however, its effective dose in different disease states remains …

Introduction Recent trials using cannabidiol (CBD) have shown that most acute and
prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects …

Background: Currently, there is a great interest in the potential medical use of cannabidiol
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …

Cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, has multiple
pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti …

Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing
attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory …

Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but
there is uncertainty about its safety. We conducted the first systematic review and meta …

Abstract The European Commission has determined that cannabidiol (CBD) can be
considered as a novel food (NF), and currently, 19 applications are under assessment at …